Omega Protein Announces First Quarter 2014 Financial Results - WSFX - FOX Wilmington, NC

Omega Protein Announces First Quarter 2014 Financial Results

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Omega Protein Corporation

HOUSTON, May 7, 2014 /PRNewswire/ -- Omega Protein Corporation (NYSE: OME), a nutritional product company and a leading integrated producer of omega-3 fish oil and specialty protein products, today reported financial results for the first quarter ended March 31, 2014.

Omega Protein Corporation Logo.

First Quarter Highlights

  • Revenues: $63.5 million for the quarter, compared to $48.9 million in the same period a year ago
  • Gross profit margin: 32.3% for the quarter, compared to 24.7% in the same period a year ago
  • Net income: $8.0 million, or $9.0 million excluding plant closure charges and loss on disposal of assets for the quarter, compared to $2.8 million, or $3.1 million excluding the loss on disposal of assets, in the same period a year ago
  • Earnings per diluted share: $0.37, or $0.42 excluding plant closure charges and loss on disposal of assets for the quarter, compared to $0.14, or $0.15 excluding the loss on disposal of assets, in the same period a year ago
  • Adjusted EBITDA: $19.1 million for the quarter, compared to $10.0 million in the same period a year ago

"We continue to see strong momentum in both our animal and human nutrition segments. These results helped us generate yet another quarter of year-over-year margin and earnings growth," commented Bret Scholtes, Omega Protein's President and Chief Executive Officer. "Our business continues to benefit from favorable animal nutrition supply and demand dynamics and we are increasingly pleased with our improved human nutrition results as we further execute on our strategic initiatives to expand our value-added product offerings for consumers."

First Quarter 2014 Results

The Company's revenues increased 30% from $48.9 million in the same period last year to $63.5 million. This increase was due to a $12.9 million increase in animal nutrition revenues and a $1.6 million increase in human nutrition revenues. The increase in animal nutrition revenues was primarily due to increased sales prices of 15% and 1% for the Company's fish meal and fish oil, respectively, and increased sales volumes for the Company's fish oil of 88%, partially offset by decreased sales volumes of 9% for the Company's fish meal. The increase in human nutrition revenues was primarily due to sales of protein products from Wisconsin Specialty Protein ("WSP"), a business acquired by the Company in the first quarter of 2013. The composition of revenue by nutritional product line for the first quarter of 2014 was 45% fish meal, 40% fish oil, 13% dietary supplements and food, and 2% fish solubles and other.

First quarter of 2014 revenues decreased 4% from $66.0 million in the fourth quarter of 2013 to $63.5 million. This decrease was due to a decrease in animal nutrition and human nutrition revenues of $1.4 million and $1.1 million, respectively. The decrease in animal nutrition revenues was primarily due to 29% lower fish meal sales volumes and 24% lower fish oil sales prices, partially offset by 4% higher fish meal sales prices and 94% higher fish oil sales volumes. The decrease in fish oil sales prices was due to a change in the product mix of higher priced refined and lower priced crude oils, and lower prices on those products. The decrease in human nutrition revenues was primarily due to lower revenues from other nutraceuticals and third party tolling.

The Company reported gross profit of $20.5 million, or 32.3% as a percentage of revenues, for the first quarter of 2014, versus $12.1 million, or 24.7% as a percentage of revenues, in the first quarter of 2013. The increase was primarily due to an increase in the animal nutrition segment gross profit as a percentage of revenues from 26.6% to 34.6% as a result of increased fish meal and fish oil sales prices. Human nutrition gross profit also increased as a percentage of revenues from 13.0% to 16.9%, due primarily to improved results from Omega-3 fish oil ingredients, partially offset by a decrease in gross profit as a percentage of revenue in the protein products business.

Compared to the fourth quarter of 2013, first quarter gross profit decreased from $28.0 million, or 42.4% as a percentage of revenues, to $20.5 million, or 32.3% as a percentage of revenues. The decrease in gross profit as a percentage of revenues was due to a decrease in animal nutrition gross profit as a percentage of revenues from 47.1% to 34.6%, primarily as a result of greater than anticipated fish catch in the fourth quarter, which resulted in additional profit related to prior period sales of 2013 inventory production, and the decreased fish oil sales prices in the first quarter. This decrease was partially offset by an increase in human nutrition segment gross profit as a percentage of revenues from 13.6% to 16.9% primarily due to improved gross profit as a percentage of revenues for other nutraceuticals.

Selling, general and administrative expenses for the first quarter decreased $0.4 million to $6.1 million compared to the first quarter of 2013, primarily as a result of lower acquisition-related professional expenses. Selling, general and administrative expenses increased $0.2 million from $5.9 million for the fourth quarter of 2013.

In the fourth quarter of 2013, the Company closed its menhaden fish processing plant located in Cameron, Louisiana and re-deployed certain vessels from that facility to the Company's other Gulf Coast facilities located in Abbeville, Louisiana and Moss Point, Mississippi, as previously announced. In conjunction with the closure, the Company incurred charges of $1.3 million in the first quarter of 2014 and $6.6 million in the fourth quarter of 2013.

The first quarter of 2014 effective tax rate was 33.9% compared to 33.2% in the first quarter of 2013 and 31.9% in the fourth quarter of 2013.

Net income for the first quarter of 2014 was $8.0 million ($0.37 per diluted share) compared to $2.8 million ($0.14 per diluted share) in the same period last year and $9.7 million ($0.45 per diluted share) for the fourth quarter of 2013. Excluding plant closure charges and gain/loss on disposal of assets, net income for the first quarter of 2014 would have been $9.0 million ($0.42 per diluted share), compared to $3.1 million ($0.15 per diluted share) in the same period last year and $14.2 million ($0.66 per diluted share) for the fourth quarter of 2013.

Adjusted EBITDA totaled $19.1 million for the first quarter of 2014, compared to $10.0 million for the same period last year and $26.7 million for the fourth quarter of 2013.

Balance Sheet

The Company's March 31, 2014 cash balance increased $7.1 million from December 31, 2013 to $41.2 million. Total debt decreased $1.2 million from December 31, 2013 to $23.0 million on March 31, 2014. Stockholders' equity increased $8.5 million to $255.7 million as of March 31, 2014 compared to $247.2 million as of December 31, 2013.

Conference Call Information

Omega Protein will host a conference call on its first quarter 2014 financial results at 8:30 a.m., Eastern Time, on Thursday, May 8, 2014. The Company's senior management team will be available to discuss recent financial results and current business trends as well as respond to questions.

Please dial (877) 407-3982 domestically or (201) 493-6780 internationally to join the call. Interested parties may also listen to the webcast live over the Internet at www.omegaprotein.com.  

A webcast replay of the conference call will be available beginning shortly after the conclusion of the call at www.omegaprotein.com and will be available for 30 days. A telephonic replay of the conference call will be available through May 22, 2014. Domestic listeners can dial (877) 870-5176, and international listeners may dial (858) 384-5517. The replay access code is 13580483.

About Omega Protein

Omega Protein Corporation (NYSE: OME) is a century old nutritional company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of functional foods, dietary supplements and animal feeds. Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined omega-3 rich fish oil, specialty proteins and nutraceuticals.

Forward Looking Statements

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Forward-looking information may be based on projections, predictions and estimates. Some statements in this press release may be forward-looking and use words like "may," "may not," "believes," "do not believe," "expects," "do not expect," "anticipates," "do not anticipate," "see," "do not see," "should," or other similar expressions. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company's ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions, natural and other disasters and disease; (2) the impact of laws and regulations that may be enacted that may restrict the Company's operations or the sale of the Company's products; (3) the impact of worldwide supply and demand relationships on prices for the Company's products; (4) the Company's expectations regarding demand and pricing for its products proving to be incorrect, and the effect of forward sales of products on the Company's financial results; (5) fluctuations in the Company's quarterly operating results due to the seasonality of the Company's business, estimates of standard cost for inventory and subsequent adjustments to such costs, and the Company's deferral of inventory sales based on worldwide prices for competing products; (6) the Company's ability to realize the anticipated benefits from its acquisitions in the human nutrition business, Nutegrity; (7) the Company's expectations regarding Nutegrity, its future prospects and the dietary supplement market or the human health and wellness segment generally, proving to be incorrect; (8) the cost of compliance with existing and future government regulations; (9) the impact of the Company's settlement with U.S. Attorney's Office on the Company's operations and financial results, including the impact of any failure to comply with the terms of the Company's probation or the limitations imposed on the Company's ability to secure government contracts or loans under the NFMS Title XI program; (10) the impact of the closure of the Company's Cameron, Louisiana processing plant on the Company's operations and financial results; and (11) the cost of compliance or potential restrictions on sales caused by laws and regulations regarding fish meal or oil importation into foreign jurisdictions. Other factors are described in further detail in the Company's filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form 10-Q and Form 8-K.

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(Dollars in thousands)


ASSETS


March 31, 2014


December 31, 2013

 Current assets:







    Cash and cash equivalents


$

41,166


$

34,059

    Receivables, net



28,080



21,140

    Inventories



81,415



94,339

    Deferred tax asset, net



917



1,062

    Prepaid expenses and other current assets



2,297



3,915








      Total current assets



153,875



154,515

Other assets, net



4,990



5,234

Property, plant and equipment, net



150,602



144,113

Goodwill



19,600



19,600

Other intangible assets, net



7,764



7,932

  Total assets


$

336,831


$

331,394








LIABILITIES AND STOCKHOLDERS' EQUITY














Current liabilities:







    Current maturities of long-term debt


$

2,538


$

3,112

    Accounts payable



4,605



5,380

    Accrued liabilities



28,254



29,145

      Total current liabilities



35,397



37,637

Long-term debt, net of current maturities



20,485



21,130

Deferred tax liability, net



19,574



19,351

Pension liabilities, net



3,705



4,117

Other long-term liabilities



1,971



1,929

    Total liabilities



81,132



84,164








Commitments and contingencies







Stockholders' equity:







    Preferred stock, $0.01 par value; 10,000,000 authorized shares; none issued



-



-

    Common Stock, $0.01 par value; 80,000,000 authorized shares; 20,906,734 and 20,804,189 shares issued and 20,902,111 and 20,804,189 shares outstanding at March 31, 2014 and December 31, 2013, respectively



204



203

    Capital in excess of par value



136,851



136,428

    Retained earnings



124,778



116,807

    Treasury stock, at cost – 4,623 shares



(57)



-

    Accumulated other comprehensive loss



(6,077)



(6,208)

                Total stockholders' equity



255,699



247,230

                    Total liabilities and stockholders' equity


$

336,831


$

331,394













 

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(In thousands, except per share amounts)




Three Months Ended



March 31,



2014



2013

Revenues

$

63,500


$

48,923

Cost of sales


43,007



36,826

Gross profit


20,493



12,097







Selling, general, and administrative expense


6,093



6,443

Research and development expense


484



555

Loss related to plant closure


1,323



-

Loss (gain) on disposal of assets


247



376

Operating income


12,346



4,723

Interest income


8



8

Interest expense


(247)



(392)

Other expense, net


(56)



(83)

Income before income taxes


12,051



4,256







Provision for income taxes


4,080



1,411

Net income


7,971



2,845







Other comprehensive income (loss):






Energy swap adjustment, net of tax (benefit) expense of ($10) and $139, respectively


(18)



257

Pension benefits adjustment, net of tax expense of $80 and $135, respectively


149



251

Comprehensive income

$

8,102


$

3,353







Basic earnings per share

$

0.38


$

0.14







Weighted average common shares outstanding


20,355



19,465







Diluted earnings per share

$

0.37


$

0.14













Weighted average common shares and potential common share equivalents outstanding


21,014



20,189

                                                                                                                                    

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Dollars in thousands)




Three Months Ended March 30,



2014



2013

Cash flows from operating activities:






       Net income

$

7,971


$

2,845

       Adjustments to reconcile net income to net cash provided by operating activities:






        Depreciation and amortization


5,217



4,977

        Loss on disposal of assets, plant closure


231



-

        Loss (gain) on disposal of assets


247



376

        Provisions for losses on receivables


12



12

        Share based compensation


392



457

        Deferred income taxes


285



497

        Changes in assets and liabilities:






                 Receivables


(6,952)



(1,270)

                 Inventories


12,716



7,007

                 Other assets


1,592



1,670

                 Accounts payable


(135)



6,971

                 Accrued liabilities


(775)



(858)

                 Pension liability, net


434



(8,196)

                 Other long term liabilities


(172)



(104)

                 Prepaid expenses and other current assets


(28)



23

                         Net cash provided by operating activities


21,035



14,407

Cash flows from investing activities:






        Proceeds from disposition of assets


61



60

        Acquisition of Wisconsin Specialty Protein, net of cash acquired


-



(26,779)

        Capital expenditures


(12,815)



(7,193)

                         Net cash used in investing activities


(12,754)



(33,912)

Cash flows from financing activities:






        Principal payments of long-term debt


(1,219)



(777)

        Principal payments of capital lease obligation


-



(151)

        Purchase treasury stock at cost


(57)



-

        Proceeds from stock options exercised


93



-

        Excess tax benefit of stock options exercised


9



-

                         Net cash provided by (used in) financing activities


(1,174)



(928)

Net decrease in cash and cash equivalents


7,107



(20,433)

Cash and cash equivalents at beginning of year


34,059



55,998

Cash and cash equivalents at end of period

$

41,166


$

35,565





 

The tables below present information about reported segments for the quarters ended March 31, 2014 and 2013 (in thousands):

2014


Animal Nutrition


Human Nutrition


Unallocated


Total

Revenue (1)           


$   55,270


$    8,230


  $          ?


$   63,500

Cost of sales        


36,167


6,840


              ?


43,007

Gross profit         


19,103


1,390


              ?


20,493

Selling, general and administrative expenses (including research and development)        


553


1,921


4,103


6,577

Loss related to plant closure           


1,323


               ?


              ?


1,323

Other (gains) and losses  


56


191


              ?


247

Operating income              


$   17,171


$     (722)


$     (4,103)


$   12,346

Depreciation and amortization       


$     4,368


$       701


$          148


$     5,217

Identifiable assets             


$ 222,761


$  71,814


$     42,256


$ 336,831

Capital expenditures         


$     4,597


$    8,209


$              9


$   12,815

 

(1)

Excludes revenue from internal customers of $0.7 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

2013


Animal Nutrition


Human Nutrition(2)


Unallocated


Total

Revenue (3)           


$   42,337


$    6,586


  $        ?


$   48,923

Cost of sales        


31,094


5,732


            ?


36,826

Gross profit         


11,243


854


            ?


12,097

Selling, general and administrative expenses (including research and development)        


628


1,296


5,074


6,998

Other (gains) and losses  


376


                 ?


            ?


376

Operating income              


$   10,239


$      (442)


$   (5,074)


$     4,723

Depreciation and amortization       


$     4,349


$        438


$        190


$     4,977

Identifiable assets             


$ 197,754


$   59,035


$   37,331


$ 294,120

Capital expenditures         


$     6,785


$        289


$        119


$     7,193

 

(2)

Includes revenues and related expenses for WSP from February 27, 2013 through March 31, 2013.



(3)

Excludes revenue from internal customers of $0.6 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

Adjusted EBITDA to Net Income Reconciliation
The following table (in thousands) provides a reconciliation of Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended March 31, 2014, December 31, 2013 and March 31, 2013:



Three Months Ended



March 31, 2014


December 31, 2013


March 31, 2013

Net Income

$

7,971

$

9,718

$

2,845

Reconciling items:







     Interest expense


216


272


361

     Income tax provision


4,080


4,553


1,411

     Depreciation and amortization


5,217


5,429


4,977

     Loss related to plant closure


1,323


6,597


-

     Impairment of intangible assets


-


186


-

     Loss (gain) on disposal of assets


247


(39)


376

Adjusted EBITDA

$

19,054

$

26,716

$

9,970

 

Adjusted EBITDA represents net income before interest expense, income tax, depreciation and amortization, impairment of intangible assets, loss related to plant closure and loss (gain) on disposal of assets. The Company has reported Adjusted EBITDA because it believes Adjusted EBITDA is a measure commonly reported and widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted EBITDA assists such investors in comparing a company's performance on a consistent basis. Adjusted EBITDA is not a calculation based on GAAP and should not be considered an alternative to net income in measuring our performance or used as an exclusive measure of cash flow because it does not consider the impact of working capital changes, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in our consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of Adjusted EBITDA. While Adjusted EBITDA has been disclosed herein to permit a more complete comparative analysis of our operating performance relative to other companies, investors should be cautioned that Adjusted EBITDA as reported by us may not be comparable in all instances to Adjusted EBITDA as reported by us or by other companies. Adjusted EBITDA amounts may not be fully available for management's discretionary use, due to certain requirements to conserve funds for capital expenditures, debt service and other commitments, and therefore management relies primarily on our GAAP results. Adjusted EBITDA is not intended to represent net income as defined by GAAP and such information should not be considered as an alternative to net income, cash flow from operations or any other measure of performance prescribed by GAAP in the United States.

Adjusted Net Income and Diluted Earnings Per Share to Net Income Reconciliation
The following table (in thousands, except per share amounts) provides a reconciliation of Adjusted Net Income and Diluted Earnings Per Share, non-GAAP (Generally Accepted Accounting Principles) financial measures, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended March 31, 2014, December 31, 2013 and March 31, 2013:



Three Months Ended



March 31, 2014


December 31, 2013


March 31, 2013

Net Income

$

7,971

$

9,718

$

2,845

Reconciling items:







     Income tax provision prior to adjustments


4,080


4,553


1,411

     Loss related to plant closure


1,323


6,597


-

     Loss (gain) on disposal of assets


247


(39)


376

Adjusted income before income taxes


13,621


20,829


4,632

     Provision for income taxes after adjustments


4,612


6,645


1,536

Adjusted net income

$

9,009

$

14,184

$

3,096

Adjusted diluted earnings per share

$

0.42

$

0.66

$

0.15

 

Adjusted net income and Adjusted diluted earnings per share represent net income and diluted earnings per share without loss related to plant closure, loss (gain) on disposal of assets and taxes associated with these items. The Company has reported Adjusted net income and Adjusted diluted earnings per share because it believes these measures are widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted net income and Adjusted diluted earnings per share assist investors in comparing a company's performance on a consistent basis.  Adjusted net income and Adjusted diluted earnings per share are not calculations based on GAAP and should not be considered alternatives to net income or diluted earnings per share in measuring our performance. Investors should carefully consider the specific items included in our computation of Adjusted net income and Adjusted diluted earnings per share. While Adjusted net income and Adjusted diluted earnings per share has been disclosed herein to permit a more complete comparative analysis of our operating performance across time periods and relative to other companies, investors should be cautioned that these measures as reported by us may not be comparable in all instances to Adjusted net income and Adjusted diluted earnings per share as reported by us or by other companies. Adjusted net income and Adjusted diluted earnings per share are not intended to represent net income or diluted earnings per share as defined by GAAP and such information should not be considered as an alternative to net income, diluted earnings per share or any other measure of performance prescribed by GAAP in the United States.

Logo - http://photos.prnewswire.com/prnh/20120717/NE41641LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WSFX. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
FCC Public File
Email: publicfile@wsfx.com
Phone: (910) 791-8070
EEO Report
Closed Captioning